Determinants of utilisation differences for cancer medicines in Belgium, Scotland and Sweden

Ferrario, Alessandra (2017) Determinants of utilisation differences for cancer medicines in Belgium, Scotland and Sweden. European Journal of Health Economics, 18 (9). pp. 1095-1105. ISSN 1618-7598

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (960kB) | Preview

Abstract

Background Little comparative evidence is available on utilisation of cancer medicines in different countries and its determinants. The aim of this study was to develop a statistical model to test the correlation between utilisation and possible determinants in selected European countries. Methods A sample of 31 medicines for cancer treatment that obtained EU-wide marketing authorisation between 2000 and 2012 was selected. Annual data on medicines’ utilisation covering the in- and out-patient public sectors were obtained from national authorities between 2008 and 2013. Possible determinants of utilisation were extracted from HTA reports and complemented by contacts with key informants. A longitudinal mixed effect model was fitted to test possible determinants of medicines utilisation in Belgium, Scotland and Sweden. Results In the all-country model, the number of indications reimbursed positively correlated with increased consumption of medicines [one indication 2.6, 95% CI (1.8–3.6); two indications 2.4, 95% CI (1.4–4.3); three indications 4.9, 95% CI (2.2–10.9); all P < 0.01], years since EU-wide marketing authorisation [1.2, 95% CI (1.02–1.4); p < 0.05], price per DDD [0.9, 95% CI (0.998–0.999), P < 0.01], and Prescrire rating [0.5, 95% CI (0.3–0.9), P < 0.05] after adjusting for time and other covariates. Conclusions In this study, the most important correlates of increased utilisation in a sample of cancer medicines introduced in the past 15 years were: medicines coverage and time since marketing authorisation. Prices had a negative effect on consumption in Belgium and Sweden. The positive impact of financial MEAs in Scotland suggests that the latter may remove the regressive effect of list prices on consumption

Item Type:	Article
Official URL:	http://link.springer.com/journal/10198
Additional Information:	© 2016 The Author © CC BY 4.0
Divisions:	Social Policy LSE Health
Subjects:	R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine
JEL classification:	I - Health, Education, and Welfare > I1 - Health > I11 - Analysis of Health Care Markets
Date Deposited:	10 Jan 2017 17:20
Last Modified:	07 Mar 2024 17:48
URI:	http://eprints.lse.ac.uk/id/eprint/68806

Actions (login required)

View Item